Actos is a prescription drug used to treat type 2 diabetes. The FDA has issued a warning that Actos (pioglitazone hydrochloride) may be linked to an increased risk of bladder cancer, especially in patients who use the medication for more than one year. This FDA information is based on a review of data from a planned five-year interim analysis of an ongoing ten-year study.
The study suggests patients who took pioglitazone for a prolonged time period and at a high dosage have an increased risk of bladder cancer.
If you or your loved one has been injured by Actos and have been diagnosed with bladder cancer, the manufacturer may have failed in its duty to label the product appropriately. Contact Bernstein & Associates today at 702-240-0000.
-Edward M Bernstein and Associates